Fiduciary Alliance LLC Makes New $1.86 Million Investment in IQVIA Holdings Inc. (NYSE:IQV)

Fiduciary Alliance LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 7,488 shares of the medical research company’s stock, valued at approximately $1,864,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in IQVIA during the fourth quarter valued at about $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of IQVIA by 339.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company’s stock worth $478,308,000 after buying an additional 1,597,003 shares in the last quarter. Morningstar Investment Services LLC raised its position in IQVIA by 96.9% in the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company’s stock valued at $286,704,000 after purchasing an additional 606,333 shares during the last quarter. Capital Research Global Investors grew its holdings in IQVIA by 42.2% during the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company’s stock worth $461,675,000 after acquiring an additional 592,372 shares during the last quarter. Finally, Cadian Capital Management LP acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $70,108,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. The Goldman Sachs Group started coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price target on the stock. Truist Financial dropped their price objective on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research note on Friday, May 3rd. Barclays decreased their price objective on IQVIA from $275.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Evercore ISI decreased their target price on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating on the stock in a report on Friday, May 3rd. Three analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $257.73.

IQVIA Stock Performance

NYSE IQV traded down $1.31 during trading hours on Friday, hitting $211.44. The company’s stock had a trading volume of 5,448,174 shares, compared to its average volume of 1,310,028. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88. The company’s 50 day simple moving average is $223.93 and its two-hundred day simple moving average is $230.15. The company has a market cap of $38.52 billion, a P/E ratio of 28.89, a price-to-earnings-growth ratio of 1.93 and a beta of 1.53.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, topping the consensus estimate of $2.19 by $0.11. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The firm had revenue of $3.74 billion for the quarter, compared to the consensus estimate of $3.69 billion. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.